KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) EBT (2016 - 2025)

Historic EBT for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $3.3 billion.

  • Pfizer's EBT fell 2928.95% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year increase of 25548.16%. This contributed to the annual value of $8.0 billion for FY2024, which is 65831.76% up from last year.
  • Pfizer's EBT amounted to $3.3 billion in Q3 2025, which was down 2928.95% from $3.0 billion recorded in Q2 2025.
  • Pfizer's EBT's 5-year high stood at $11.4 billion during Q3 2022, with a 5-year trough of -$4.1 billion in Q4 2023.
  • For the 5-year period, Pfizer's EBT averaged around $4.3 billion, with its median value being $4.1 billion (2024).
  • As far as peak fluctuations go, Pfizer's EBT crashed by 13724.03% in 2023, and later surged by 305533.98% in 2025.
  • Over the past 5 years, Pfizer's EBT (Quarter) stood at $7.8 billion in 2021, then rose by 14.76% to $9.0 billion in 2022, then tumbled by 145.87% to -$4.1 billion in 2023, then soared by 214.19% to $4.7 billion in 2024, then decreased by 29.29% to $3.3 billion in 2025.
  • Its EBT stands at $3.3 billion for Q3 2025, versus $3.0 billion for Q2 2025 and $2.8 billion for Q1 2025.